Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication

Executive Summary

FDA's full approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib) covers both refractory and first-line use

You may also be interested in...



Torisel’s Positive Effect on Overall Survival Expected To Drive Sales

Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch

Torisel’s Positive Effect on Overall Survival Expected To Drive Sales

Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch

Stable Cancer Patients Phase I Dosing Could Be Extended If Benefit Shown

A Phase I trial participant should be allowed to continue receiving an investigational oncology compound beyond the duration of animal safety data if he has stable disease and he and his physician agree that this represents a benefit from therapy, FDA's Oncologic Drugs Advisory Committee said March 13

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel